UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway

References

• Nguyen HM, Guz-Montgomery K, Lowe DB, Saha D. Pathogenetic features and current management of glioblastoma. Cancers. 2021;13(4):856. doi:10.3390/cancers13040856
   PubMed Web of Science ®Google Scholar
• Khan I, Baig MH, Mahfooz S, et al. Nanomedicine for glioblastoma: progress and future prospects. Semin Cancer Biol. 2022;86(Pt 2):172–186. doi:10.1016/j.semcancer.2022.06.007
   PubMedGoogle Scholar
• Gan T, Wang Y, Xie M, et al. MEX3A impairs DNA mismatch repair signaling and mediates acquired temozolomide resistance in glioblastoma. Cancer Res. 2022;82(22):4234–4246. doi:10.1158/0008-5472.CAN-22-2036
   PubMed Web of Science ®Google Scholar
• Goenka A, Tiek D, Song X, Huang T, Hu B, Cheng SY. The many facets of therapy resistance and tumor recurrence in glioblastoma. Cells. 2021;10(3):484. doi:10.3390/cells10030484
   PubMed Web of Science ®Google Scholar
• Zhao J, Yang S, Cui X, et al. A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma. Neuro Oncol. 2022. doi:10.1093/neuonc/noac242
   Google Scholar
• Ntafoulis I, Koolen SLW, Leenstra S, Lamfers MLM. Drug repurposing, a fast-track approach to develop effective treatments for glioblastoma. Cancers. 2022;14(15):3705. doi:10.3390/cancers14153705
   PubMed Web of Science ®Google Scholar
• Zhu J, Ao H, Liu M, Cao K, Ma J. UBE2T promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung adenocarcinoma. J Transl Med. 2021;19(1):374. doi:10.1186/s12967-021-03056-1
   PubMed Web of Science ®Google Scholar
• Machida YJ, Machida Y, Chen Y, et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006;23(4):589–596. doi:10.1016/j.molcel.2006.06.024
   PubMed Web of Science ®Google Scholar
• Schultz-Rogers L, Lach FP, Rickman KA, et al. A homozygous missense variant in UBE2T is associated with a mild Fanconi anemia phenotype. Haematologica. 2021;106(4):1188–1192. doi:10.3324/haematol.2020.259275
   PubMed Web of Science ®Google Scholar
• Huang W, Huang H, Xiao Y, et al. UBE2T is upregulated, predicts poor prognosis, and promotes cell proliferation and invasion by promoting epithelial-mesenchymal transition via inhibiting autophagy in an AKT/mTOR dependent manner in ovarian cancer. Cell Cycle. 2022;21(8):780–791. doi:10.1080/15384101.2022.2031426
   PubMed Web of Science ®Google Scholar
• Lioulia E, Mokos P, Panteris E, Dafou D. UBE2T promotes beta-catenin nuclear translocation in hepatocellular carcinoma through MAPK/ERK-dependent activation. Mol Oncol. 2022;16(8):1694–1713. doi:10.1002/1878-0261.13111
   PubMed Web of Science ®Google Scholar
• Ren X, Li A, Ying E, Fang J, Li M, Yu J. Upregulation of ubiquitin-conjugating enzyme E2T (UBE2T) predicts poor prognosis and promotes hepatocellular carcinoma progression. Bioengineered. 2021;12(1):1530–1542. doi:10.1080/21655979.2021.1918507
   PubMed Web of Science ®Google Scholar
• Yu Z, Jiang X, Qin L, et al. A novel UBE2T inhibitor suppresses Wnt/beta-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination. Oncogene. 2021;40(5):1027–1042. doi:10.1038/s41388-020-01572-w
   PubMed Web of Science ®Google Scholar
• Ho NPY, Leung CON, Wong TL, et al. The interplay of UBE2T and mule in regulating Wnt/beta-catenin activation to promote hepatocellular carcinoma progression. Cell Death Dis. 2021;12(2):148. doi:10.1038/s41419-021-03403-6
   PubMed Web of Science ®Google Scholar
• Cui P, Li H, Wang C, et al. UBE2T regulates epithelial-mesenchymal transition through the PI3K-AKT pathway and plays a carcinogenic role in ovarian cancer. J Ovarian Res. 2022;15(1):103. doi:10.1186/s13048-022-01034-9
   PubMed Web of Science ®Google Scholar
• Li Y, Yang X, Lu D. Knockdown of ubiquitin-conjugating enzyme E2T (UBE2T) suppresses lung adenocarcinoma progression via targeting fibulin-5 (FBLN5). Bioengineered. 2022;13(5):11867–11880. doi:10.1080/21655979.2022.2060162
   PubMed Web of Science ®Google Scholar
• Zhu Z, Cao C, Zhang D, et al. UBE2T-mediated Akt ubiquitination and Akt/beta-catenin activation promotes hepatocellular carcinoma development by increasing pyrimidine metabolism. Cell Death Dis. 2022;13(2):154. doi:10.1038/s41419-022-04596-0
   PubMed Web of Science ®Google Scholar
• Yin H, Wang X, Zhang X, et al. UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation. Cancer Lett. 2020;494:121–131. doi:10.1016/j.canlet.2020.06.005
   PubMed Web of Science ®Google Scholar
• Sun J, Zhu Z, Li W, et al. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation. J Exp Clin Cancer Res. 2020;39(1):222. doi:10.1186/s13046-020-01734-4
   PubMed Web of Science ®Google Scholar
• Ramaekers CH, van den Beucken T, Meng A, et al. Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiother Oncol. 2011;101(1):190–197. doi:10.1016/j.radonc.2011.05.059
   PubMed Web of Science ®Google Scholar
• Tao X, Wu X, Zhou P, et al. UBE2T promotes glioblastoma malignance through ubiquitination-mediated degradation of RPL6. Cancer Sci. 2022;114:521–532. doi:10.1111/cas.15604
   PubMed Web of Science ®Google Scholar
• Huang P, Guo Y, Zhao Z, et al. UBE2T promotes glioblastoma invasion and migration via stabilizing GRP78 and regulating EMT. Aging. 2020;12(11):10275–10289. doi:10.18632/aging.103239
   PubMedGoogle Scholar
• Lee R, Li J, Li J, et al. Synthetic essentiality of tryptophan 2,3-Dioxygenase 2 in APC-mutated colorectal cancer. Cancer Discov. 2022;12(7):1702–1717. doi:10.1158/2159-8290.CD-21-0680
   PubMed Web of Science ®Google Scholar
• Lu Y, Zhao X, Liu Q, et al. lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/beta-catenin signaling. Nat Med. 2017;23(11):1331–1341. doi:10.1038/nm.4424
   PubMed Web of Science ®Google Scholar
• He Z, Cheng M, Hu J, et al. miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM). J Transl Med. 2022;20(1):443. doi:10.1186/s12967-022-03647-6
   PubMed Web of Science ®Google Scholar
• Cantidio FS, Gil GOB, Queiroz IN, Regalin M. Glioblastoma - treatment and obstacles. Rep Pract Oncol Radiother. 2022;27(4):744–753. doi:10.5603/RPOR.a2022.0076
   PubMedGoogle Scholar
• Choo M, Mai VH, Kim HS, et al. Involvement of cell shape and lipid metabolism in glioblastoma resistance to temozolomide. Acta Pharmacol Sin. 2022;44:670–679. doi:10.1038/s41401-022-00984-6
   PubMed Web of Science ®Google Scholar
• Chen Y, Hong H, Wang Q, et al. NEDD4L-induced ubiquitination mediating UBE2T degradation inhibits progression of lung adenocarcinoma via PI3K-AKT signaling. Cancer Cell Int. 2021;21(1):631. doi:10.1186/s12935-021-02341-9
   PubMed Web of Science ®Google Scholar
• Qiao L, Dong C, Ma B. UBE2T promotes proliferation, invasion and glycolysis of breast cancer cells by regulating the PI3K/AKT signaling pathway. J Recept Signal Transduct Res. 2022;42(2):151–159. doi:10.1080/10799893.2020.1870495
   PubMed Web of Science ®Google Scholar
• Hao P, Kang B, Li Y, Hao W, Ma F. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma. Mol Med Rep. 2019;20(2):1212–1220. doi:10.3892/mmr.2019.10322
   PubMed Web of Science ®Google Scholar
• Wang Y, Leng H, Chen H, et al. Knockdown of UBE2T inhibits osteosarcoma cell proliferation, migration, and invasion by suppressing the PI3K/Akt signaling pathway. Oncol Res. 2016;24(5):361–369. doi:10.3727/096504016X14685034103310
   PubMed Web of Science ®Google Scholar
• Xu N, Cui Y, Shi H, et al. UBE2T/STAT3 signaling promotes the proliferation and tumorigenesis in retinoblastoma. Invest Ophthalmol Vis Sci. 2022;63(9):20. doi:10.1167/iovs.63.9.20
   Web of Science ®Google Scholar
• Liu J, Xiao Q, Xiao J, et al. Wnt/beta-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022;7(1):3. doi:10.1038/s41392-021-00762-6
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang X. Targeting the Wnt/beta-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13(1):165. doi:10.1186/s13045-020-00990-3
   PubMed Web of Science ®Google Scholar
• Perugorria MJ, Olaizola P, Labiano I, et al. Wnt-beta-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(2):121–136. doi:10.1038/s41575-018-0075-9
   PubMed Web of Science ®Google Scholar
• Zhao H, Ming T, Tang S, et al. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer. 2022;21(1):144. doi:10.1186/s12943-022-01616-7
   PubMed Web of Science ®Google Scholar
• Barzegar Behrooz A, Talaie Z, Jusheghani F, Los MJ, Klonisch T, Ghavami S. Wnt and PI3K/Akt/mTOR survival pathways as therapeutic targets in glioblastoma. Int J Mol Sci. 2022;23(3):1353. doi:10.3390/ijms23031353
   PubMed Web of Science ®Google Scholar
• Shahcheraghi SH, Tchokonte-Nana V, Lotfi M, Lotfi M, Ghorbani A, Sadeghnia HR. Wnt/beta-catenin and PI3K/Akt/mTOR signaling pathways in glioblastoma: two main targets for drug design: a review. Curr Pharm Des. 2020;26(15):1729–1741. doi:10.2174/1381612826666200131100630
   PubMed Web of Science ®Google Scholar
• Sun J, Ma Q, Li B, et al. RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/beta-catenin signaling pathway. Cell Death Dis. 2020;11(10):890. doi:10.1038/s41419-020-03113-5
   PubMed Web of Science ®Google Scholar
• Wickstrom M, Dyberg C, Milosevic J, et al. Wnt/beta-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun. 2015;6:8904. doi:10.1038/ncomms9904
   PubMed Web of Science ®Google Scholar
• Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021;4(1):17–43. doi:10.20517/cdr.2020.79
   PubMedGoogle Scholar